AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation

The FDA approved on Wednesday AstraZeneca Plc’s (NASDAQ:AZN) Fasenra (benralizumab) for eosinophilic granulomatosis with polyangiitis (EGPA), a rare, immune-mediated vasculitis (inflammation of the blood vessels) that can result in damage to multiple organs.

The approval was based on data from the MANDARA Phase 3 trial published in The New England Journal of Medicine, which compared the efficacy and safety of Fasenra to the only approved EGPA treatment, GSK Plc’s (NYSE:GSK) Nucala (mepolizumab).

Also Read: AstraZeneca CEO Pascal Soriot Updates On ...